Vaccinex(OTC) VCNX

Vaccinex, Inc. is a biotechnology firm focused on developing specialized biological therapies for serious medical conditions. The company is dedicated to addressing diseases that currently lack effective treatment options, with a robust pipeline that includes innovative therapies for various cancers and neurodegenerative disorders.

Products and Services

• Pepinemab, a humanized monoclonal antibody in clinical trials
• VX5, targeting CXCL13 for autoimmune conditions
• Research and development in cancer and neurodegenerative diseases

Growth Outlook

• Ongoing Phase 1b/2 trials for pepinemab in multiple cancers
• Preclinical assessment of VX5 for multiple sclerosis
• Expansion into neurodegenerative disorders like Alzheimer's and Huntington's disease

Financial Highlights

• Q4 2024 revenue of $213,000, showing growth potential
• Trailing twelve months (TTM) revenue of $1,000,000, indicating market interest
• Cash and cash equivalents of $1,107,000 as of Q4 2024

Vaccinex, Inc. operates in the clinical stage of biotechnology, emphasizing the development of therapies for conditions with significant unmet needs. The company's lead candidate, pepinemab, is undergoing trials for various cancers, showcasing its commitment to innovative treatment solutions. Additionally, the preclinical work on VX5 highlights the potential for addressing autoimmune diseases, further diversifying the company's therapeutic focus. Recent financial data indicates a revenue of $213,000 for Q4 2024, reflecting a growing interest in the company's offerings. The trailing twelve months revenue of $1,000,000 suggests a solid foundation for future growth. With cash and cash equivalents totaling $1,107,000, Vaccinex is positioned to continue its research and development efforts, aiming to bring its promising therapies to market. The company's strategic focus on serious medical conditions, combined with its innovative pipeline, presents a compelling opportunity for potential investors interested in the biotechnology sector.